PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights financial challenges, including a net loss and cash constraints, despite revenue growth. Regulatory compliance issues and potential dilution from Series B conversion add to investor concerns. The Q&A reveals management's evasive responses and competitive pressures. While there is optimism about human trials, the overall sentiment is negative due to financial sustainability issues and market penetration challenges.
Key Financial Performance
Revenue $1.1 million, a 17% increase year-over-year. This growth was largely driven by the expanding nationwide distributor network, with their combined sales increasing 31% to $958,000 and representing 85% of total revenue for the year.
Gross Profit $995,000 or 87.8% of revenues, a 15% increase compared to $867,000 or 89.5% of revenues in fiscal '24. The slight decrease in gross margin percentage was due to changes in revenue mix.
Operating Expenses $9.1 million, a 21% decrease compared to $11.5 million in fiscal year '24. This reduction was due to a strategic company-wide cost reduction and restructuring program.
Net Loss $8 million or $0.39 per share, a 27% improvement from a net loss of $11 million or $0.78 per share in fiscal '24. This improvement was primarily due to cost reduction and restructuring efforts.
Net Cash Used in Operating Activities Decreased by 40%, resulting in $2.9 million savings compared to fiscal 2024. This was primarily due to the strategic cost reduction and restructuring program.
Cash and Cash Equivalents $227,689 at March 31, 2025, compared to $87,403 at March 31, 2024. The increase was primarily due to proceeds from equity financings conducted during the year.
Total Assets $9.3 million at March 31, 2025, compared to $3.1 million at March 31, 2024. The increase was primarily due to proceeds from equity financings.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Spryng with OsteoCushion technology: Expanded use across 1,000+ veterinary clinics in all 50 states and first distributor in Mexico. Targeting equine and companion animal markets.
PrecisePRP: Exclusive licensing and supply agreement with VetStem for commercialization. First-in-class, off-the-shelf platelet-rich plasma product for horses and dogs.
North American expansion: 17% revenue growth to $1.1 million, driven by expanded distributor network and increased focus on companion animal market.
International expansion: Entry into Mexico with a distributor, targeting a $2 billion veterinary market by 2026.
Cost reduction and restructuring: Operating expenses decreased by 21%, with strategic reductions in general, administrative, and sales expenses.
Leadership and team expansion: Appointment of Mike Eldred as Commercialization & Operations Advisor and April Boyce as VP of Sales and Marketing. Deployment of new territory managers and sales representatives.
AI integration: Strategic alliance with Digital Landia to integrate pet AI technology for real-time animal behavior analysis.
Partnerships: Collaborations with Commonwealth Markets for equine health and PiezoBioMembrane for biomaterials research.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance: The company has filed for an extension for its Form 10-K filing to allow auditors to complete their audit, particularly for derivatives accounting. This delay could pose risks related to regulatory compliance and investor confidence.
Financial Sustainability: Despite revenue growth, the company reported a net loss of $8 million for fiscal 2025. Although this is an improvement from the previous year, the losses highlight ongoing financial challenges.
Cash Flow Constraints: Cash and cash equivalents were limited to $227,689 at the end of fiscal 2025, though subsequent funding raised this to $3.3 million. Limited cash reserves could impact operational flexibility.
Market Penetration Challenges: While the company has expanded its distributor network and entered the Mexican market, achieving significant penetration in the larger companion animal market remains a challenge.
Dependence on Clinical Studies: The company relies heavily on clinical studies to validate its products for veterinarians and distributors. Delays or unfavorable outcomes in these studies could hinder product adoption.
Competitive Pressures: The animal health market is growing rapidly, but competition from established players could limit the company's market share and growth potential.
Operational Risks: The company is undergoing restructuring and cost reduction efforts. While these have reduced expenses, they may also disrupt operations or impact employee morale.
Technology Integration Risks: The integration of new technologies like Digital Landia's pet AI and partnerships with PiezoBioMembrane involves complexities and uncertainties that could delay or derail these initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to continue strong sales momentum and market penetration in fiscal 2026, building on a 17% revenue growth in fiscal 2025. The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities.
Market Expansion: PetVivo plans to expand its presence in high-growth markets, including the companion animal market and international markets such as Mexico, where the veterinary healthcare market is projected to grow at a 6% CAGR to nearly $2 billion by 2026.
Product Development and Commercialization: The company is focusing on the commercialization and market penetration of its lead products, Spryng and PrecisePRP, supported by new clinical trials and studies. Additional products are expected to be added to the platform.
Strategic Partnerships: PetVivo has entered into strategic alliances, including a collaboration with Digital Landia for AI technology integration and partnerships with Commonwealth Markets and PiezoBioMembrane for advanced veterinary solutions. These partnerships aim to enhance product offerings and market visibility.
Operational Enhancements: The company has restructured its sales and marketing teams, added new distributors, and implemented cost reduction measures to improve operational efficiency and support growth strategies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much dilution is expected from the conversion of the Series B preferred?
A:The Series B preferred converts on a one-to-one basis. It was sold at a premium of $1 per share, compared to the stock's trading price of $0.55 at the time of the initial transaction. If fully converted, it would result in an additional 5 million shares.
Q:What is the average price per vial of the Spryng injection that veterinarians charge for canines?
A:Veterinarians charge an average of $800 per joint for the Spryng injection. Prices range from $500 to $1,200 depending on the region, the veterinarian, and the complexity of the problem.
Q:Is the $500 to $1,200 price range based on volume discounts to the veterinary clinic?
A:No, the $500 to $1,200 range reflects what veterinarians charge clients. The price veterinarians pay is confidential due to distribution agreements, but it can be inferred from the company's gross profit margin.
Q:Can you talk about the human trials and their projected path?
A:The human trials are linked to a partnership with Piezo, which has conducted small and large animal studies at the University of Connecticut. Early results show promising regeneration within scaffolding using nanofiber technology and ultrasound. The human osteoarthritis market is valued at $11.2 billion in the U.S. and $33 billion globally, and the company hopes to demonstrate efficacy in this space.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about the price veterinarians pay for the Spryng injection, citing confidentiality due to distribution agreements. Instead, they suggested looking at the company's gross profit margin for an idea of the pricing.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Digital Landia
Eldred
Form filing
Mexico
PetVivo veterinarian
Vedco Clipper
Vet
Vice President
addition
adoption PrecisePRP
advancement
animal market
auditor audit
care
cash
change Form
collaboration Commonwealth
commercialization
development
distributor network
effort
equine market
expansion
horse
increase
industry
marketing
partnership
pet
platform
solution
technology
treatment
year experience
PETV Transcript
PetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call Transcript
Unknown2-17
The earnings call summary indicates mixed signals: improved balance sheet and strategic cost reductions are positive, but increased operating loss and lack of clear guidance are concerning. The Q&A reveals management's uncertainty about guidance and revenue expectations, which could worry investors. While there are promising developments in product launches and market expansion, the absence of NASDAQ listing plans and unclear future projections temper enthusiasm, leading to a neutral sentiment.
PetVivo Holdings, Inc. (PETV) Q2 2026 Earnings Call Transcript
Positive11-14
The earnings call revealed strong revenue growth and market expansion potential, particularly in the animal health sector. Despite a decrease in gross margins and an increased net loss, the company's strategic initiatives, including partnerships and product launches, are promising. The Q&A highlighted management's transparency about revenue sources and adoption challenges, though specifics were lacking. The strategic partnerships and record revenue growth are positive indicators. Given these factors, the stock price is likely to see a positive movement over the next two weeks.
PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript
Unknown8-14
The earnings call summary shows mixed signals: strong revenue growth and new partnerships are positive, but high operating losses, cash flow concerns, and reliance on distributors are negative. The Q&A didn't reveal new insights or strong analyst sentiment. Despite record revenue growth, margin pressure and financial health concerns weigh heavily, balancing out the positives. Without clear guidance or market cap data, the overall sentiment is neutral, suggesting a stock price movement within the -2% to 2% range.
PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript
Unknown6-30
The earnings call highlights financial challenges, including a net loss and cash constraints, despite revenue growth. Regulatory compliance issues and potential dilution from Series B conversion add to investor concerns. The Q&A reveals management's evasive responses and competitive pressures. While there is optimism about human trials, the overall sentiment is negative due to financial sustainability issues and market penetration challenges.
PETV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
